Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

被引：113
作者：
Gazi, Irene F.
Tsimihodimos, Vasilis
Tselepis, Alexandros D.
Elisaf, Moses
Mikhailidis, Dimitri P.
机构：
[1] Royal Free Hosp, Dept Clin Biochem, London NW3 2QG, England
[2] Univ Coll Med, London NW3 2QG, England
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 01期
关键词：
atherosclerosis; cardiovascular disease; diabetes mellitus; fibrates; metabolic syndrome; small dense low-density lipoprotein; statins; triglycerides;
D O I：
10.1517/14712598.7.1.53
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The National Cholesterol Education Programme Adult Treatment Panel III accepted the predominance of small dense low-density lipoprotein (sdLDL) as an emerging cardiovascular disease (CVD) risk factor. Most studies suggest that measuring low-density lipoprotein (LDL) particle size, sdLDL cholesterol content and LDL particle number provides additional assessment of CVD risk. Therapeutic modulation of small LDL size, number and distribution may decrease CVD risk; however, no definitive causal relationship is established, probably due to the close association between sdLDL and triglycerides and other risk factors (e.g., high-density lipoprotein, insulin resistance and diabetes). This review addresses the formation and measurement of sdLDL, as well as the relationship between sdLDL particles and CVD. The effect of hypolipidaemic (statins, fibrates and ezetimibe) and hypoglycaemic (glitazones) agents on LDL size and distribution is also discussed.
引用
收藏
页码：53 / 72
页数：20
相关论文
共 310 条
[31]   COMPARISON OF GEMFIBROZIL VERSUS SIMVASTATIN IN FAMILIAL COMBINED HYPERLIPIDEMIA AND EFFECTS ON APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS, LOW-DENSITY-LIPOPROTEIN SUBFRACTION PROFILE, AND LOW-DENSITY-LIPOPROTEIN OXIDIZABILITY [J].
BREDIE, SJH ;
DEBRUIN, TWA ;
DEMACKER, PNM ;
KASTELEIN, JJP ;
STALENHOEF, AFH .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (05) :348-353
[32]   Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol [J].
Brousseau, ME ;
Schaefer, EJ ;
Wolfe, ML ;
Bloedon, LT ;
Digenio, AG ;
Clark, RW ;
Mancuso, JP ;
Rader, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1505-1515
[33]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[34]   Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus [J].
Brunzell, JD ;
Ayyobi, AF .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 :24-28
[35]   Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses [J].
Calabresi, L ;
Donati, D ;
Pazzucconi, F ;
Sirtori, CR ;
Franceschini, G .
ATHEROSCLEROSIS, 2000, 148 (02) :387-396
[36]  
Camejo G, 2003, INT J CLIN PRACT, P36
[37]   The clinical significance of PPAR gamma agonism [J].
Campbell, IW .
CURRENT MOLECULAR MEDICINE, 2005, 5 (03) :349-363
[38]   Low-density lipoprotein size, pravastatin treatment, and coronary events [J].
Campos, H ;
Moye, LA ;
Glasser, SP ;
Stampfer, MJ ;
Sacks, FM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (12) :1468-1474
[39]   PREDOMINANCE OF LARGE LDL AND REDUCED HDL(2) CHOLESTEROL IN NORMOLIPIDEMIC MEN WITH CORONARY-ARTERY DISEASE [J].
CAMPOS, H ;
ROEDERER, GO ;
LUSSIERCACAN, S ;
DAVIGNON, J ;
KRAUSS, RM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (08) :1043-1048
[40]   LOW-DENSITY-LIPOPROTEIN PARTICLE-SIZE AND CORONARY-ARTERY DISEASE [J].
CAMPOS, H ;
GENEST, JJ ;
BLIJLEVENS, E ;
MCNAMARA, JR ;
JENNER, JL ;
ORDOVAS, JM ;
WILSON, PWF ;
SCHAEFER, EJ .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (02) :187-195
12345678910